Cannabis Withdrawal Symptoms and How Long They Last

Two questions bring most people here, usually the same person asking twice. What is happening to me. And when does it stop. The research answers both reasonably well, which is unusual for a cannabis question.

What follows covers the symptoms and the timeline. It does not argue whether cannabis is addictive, which is a separate question about dependence, and it does not offer a plan for stopping. Both belong in a clinical conversation rather than an article.

What Are the Symptoms of Cannabis Withdrawal?

Anxiety, irritability, anger or aggression, disturbed sleep and dreaming, depressed mood, and loss of appetite. Physical symptoms are less common and include chills, headaches, physical tension, sweating, and stomach pain.

That list comes from the 2022 Addiction review of cannabis withdrawal. The review calls withdrawal a well characterized phenomenon. It follows abrupt cessation, or a significant reduction, in cannabis products containing delta-9-tetrahydrocannabinol.

The formal diagnostic threshold is narrower than the symptom list suggests. Under DSM-5, cannabis withdrawal requires three or more of the following after cessation of heavy and prolonged use, defined as daily or almost daily use over a period of at least a few months:

• Irritability, anger, or aggression
• Nervousness or anxiety
• Sleep difficulty, including insomnia and disturbing dreams
• Decreased appetite or weight loss
• Restlessness
• Depressed mood

Plus at least one physical symptom causing significant discomfort: abdominal pain, shakiness or tremors, sweating, fever, chills, or headache. The signs must cause clinically significant distress or impairment, and must not be better explained by another condition or by withdrawal from another substance.

Two features of that definition do real work. The first is the use threshold. Withdrawal is described in people who used daily or near daily for months, not in occasional users. The second is the impairment requirement. Experiencing a symptom is not the same as meeting the criteria.

How Long Does Cannabis Withdrawal Last?

Onset is typically 24 to 48 hours after stopping. Most symptoms peak between days 2 and 6. In heavy users, some symptoms can last two to three weeks or longer, and sleep disturbance may continue for several weeks beyond that.

The most detailed prospective measurement is still Budney and colleagues' 2003 study in the Journal of Abnormal Psychology. It ran 50 days: a 5-day smoking-as-usual phase followed by 45 days of abstinence in 18 marijuana users, with 12 ex-users assessed in parallel. A withdrawal pattern appeared for aggression, anger, anxiety, decreased appetite, decreased body weight, irritability, restlessness, shakiness, sleep problems, and stomach pain. Onset typically occurred between days 1 and 3, peak effects between days 2 and 6, and most effects lasted 4 to 14 days. The authors noted the magnitude and time course appeared comparable to tobacco and other withdrawal syndromes.

Duration and severity track the amount of cannabis consumed before cessation, though the 2022 review is explicit that this varies considerably between individuals.

What Does the Withdrawal Timeline Look Like Day by Day?

Not as one curve. The clinical literature describes two overlapping waves. Knowing which wave a symptom belongs to explains why people report the worst part at very different times.

The early wave is the one most people expect. It behaves the way withdrawal is supposed to: arrives fast, peaks inside a week, fades as the drug clears. The later wave is the one that catches people out. Someone who feels physically past it at day 8 and then hits their worst mood at day 14 has not relapsed into a new problem. That is the documented pattern.

Sleep is the outlier in both directions. It shows up in the early wave. It ranks among the most frequently reported symptoms overall. And it is the one most likely to still be there after everything else has cleared.

How Common Is Cannabis Withdrawal?

It depends entirely on who is counted, and the honest answer is a range rather than a number.

The largest estimate comes from a 2020 meta-analysis in JAMA Network Open pooling 47 studies across 50 cohorts and 23,518 participants. Among people with regular or dependent cannabis use, the pooled prevalence of withdrawal was 47 percent, or 6,469 of 23,518. The 95 percent confidence interval ran from 41 to 52 percent.

That headline figure conceals an enormous spread by setting:

A general-population reader is closer to the 17 percent row than the 47 percent headline. Heterogeneity across the pooled studies was very high, at an I-squared of 99.2 percent. The authors named the wide range of instruments used to define withdrawal as a limitation.

A different design gives a lower number. Livne and colleagues, in Drug and Alcohol Dependence, analyzed the nationally representative NESARC-III survey. They isolated 1,527 US adults who used cannabis three or more times a week in the prior year. Among those frequent users, 12.1 percent met DSM-5 criteria for withdrawal. Within that group the leading symptoms were nervousness or anxiety at 76.3 percent, hostility at 71.9 percent, sleep difficulty at 68.2 percent, and depressed mood at 58.9 percent.

The gap between 47 percent and 12.1 percent is not a contradiction. The meta-analysis pooled studies that measured symptoms on standardized scales, weighted heavily toward treatment-seeking samples. The survey applied the full DSM-5 threshold, including the clinically-significant-distress requirement, to a representative national sample. Different question, different answer.

Who Is Most Likely to Get Withdrawal Symptoms?

The 2020 meta-analysis found higher prevalence associated with daily cannabis use, presence of cannabis use disorder, comorbid tobacco use, and comorbid other drug use. Beyond use pattern, three individual factors appear in the literature.

Genetics. The 2022 review reports that up to 50 percent of between-individual differences in cannabis withdrawal can be attributed to genetic variation.

Sex. Some studies of regular users, and of people seeking treatment, report that females may experience more severe withdrawal than males. That holds even when the groups are matched for cannabis use and demographics. The review presents this as a finding in some studies, not a settled effect.

Age. Younger age predicted both greater severity and a worsening trajectory in the medical cannabis cohort described below.

There is also a floor effect worth naming, because it contradicts the intuition that light use means no symptoms. The 2022 review notes that some patients report low levels of use and few cannabis use disorder symptoms, yet still describe withdrawal that significantly impairs day-to-day functioning. It also states that there are limited empirical data on how physical, psychiatric, or metabolic differences contribute to severity.

Do Medical Cannabis Patients Get Withdrawal Symptoms?

Yes. The best evidence comes from a population that looks a great deal like a certification clinic waiting room, because that is exactly where it was collected.

Coughlin and colleagues followed 527 adults with chronic pain in Michigan, all of them seeking medical cannabis certification or re-certification. Recruitment ran through clinic waiting rooms from February 2014 to June 2015. Participants averaged 45.6 years old. Withdrawal symptoms were measured at baseline, 12 months, and 24 months.

A three-class model best described the sample:

• Mild symptom class: 41 percent
• Moderate symptom class: 34 percent
• Severe symptom class: 25 percent

What happened over time matters more than the split itself. Class membership was largely stable across the two-year follow-up. Stability estimates ranged from 0.58 to 0.87, highest in the mild class. Withdrawal here was not a transient artifact of one quit attempt. It persisted as a feature of the person's ongoing pattern of use. Younger age predicted both greater severity and an escalating trajectory.

The authors' own conclusion: adults with chronic pain seeking certification or re-certification appear to experience mild to severe withdrawal symptoms. Read it with the limits attached. This is one cohort, from one state, recruited a decade ago, and 82 percent white. It is not a national estimate. It is direct evidence that "medical use" is not a category the withdrawal literature exempts.

Is Cannabis Withdrawal Dangerous?

The 2022 clinical review states plainly that cannabis withdrawal does not carry a high risk of severe adverse outcomes. Elsewhere it notes there are few risks related directly to the withdrawal itself.

That is a meaningful statement in context. It distinguishes cannabis from alcohol and benzodiazepines, where unsupervised withdrawal carries recognized medical danger. It is not a statement that the experience is trivial. The same review is direct about what does complicate it:

• Existing medical or psychiatric conditions. Comorbidities such as polysubstance use and dependence may produce more severe complications and symptoms, requiring additional management.
• Concurrent withdrawal from other substances. Withdrawal from a higher-risk substance at the same time is a different clinical situation with different risks.
• Effects on mood and psychosis. If withdrawal exacerbates depression, anxiety, or psychosis, the review states that risks are increased and more regular monitoring may be clinically indicated.
• Relapse. The review identifies this as the greatest risk, because resuming use immediately relieves the symptoms. Irritability and mood effects can also strain relationships and work performance.

No medication is currently approved specifically for cannabis withdrawal. What management should look like is outside the scope of this article and belongs to a clinician who knows your history. If withdrawal symptoms involve thoughts of self-harm, seek medical help immediately. The 988 Suicide and Crisis Lifeline takes calls and texts. The SAMHSA National Helpline is free, confidential, and staffed around the clock.

Does Stopping CBD Cause Withdrawal?

The clinical review literature reports that cessation of short-term cannabidiol, a non-psychoactive cannabinoid, does not appear to result in withdrawal.

Cannabis withdrawal is described throughout the literature in relation to products containing THC specifically. That distinction is practically useful. Hemp-derived CBD products are sold openly nationwide, and they are a different exposure than the daily high-THC use the withdrawal research describes. Where that distinction breaks down in practice is a separate issue, covered in the does CBD show up on a drug test post.

Has Rising Potency Changed Any of This?

Potency has risen, and severity tracks dose. Whether the first caused a change in the second has not been directly established, and it would be an overstatement to claim it has.

The potency trend is well documented. ElSohly and colleagues analyzed 38,681 cannabis samples seized by the US Drug Enforcement Administration between 1995 and 2014. THC content rose from roughly 4 percent in 1995 to roughly 12 percent in 2014. CBD content fell over the same window, from about 0.28 percent in 2001 to under 0.15 percent in 2014. That moved the THC-to-CBD ratio from about 14 to 1 up to about 80 to 1. A follow-up analysis covering 2013 to 2022 found delta-9-THC above 10 percent in most high-THC samples.

Those are seized illicit samples, not dispensary inventory, and that limits what they say about a regulated medical product. The 2022 review's finding that duration and severity track the amount consumed before cessation is a dose relationship. It is not a potency-trend conclusion. The two facts are compatible, and no study has connected them directly.

Use is also more widespread. The 2024 National Survey on Drug Use and Health puts past-year marijuana use among people aged 12 or older at 22.3 percent, or 64.2 million people. In 2021 the same figures were 19.0 percent and 53.2 million.

Is Cannabis Withdrawal a Qualifying Condition in Florida, Georgia, or Texas?

No. Cannabis withdrawal is not a listed qualifying condition in any of the three state programs. Neither is cannabis use disorder, nor any other substance use disorder.

• Florida. Fla. Stat. 381.986 enumerates cancer, epilepsy, glaucoma, HIV, AIDS, post traumatic stress disorder, ALS, Crohn's disease, Parkinson's disease, and multiple sclerosis. Subsection (2)(k) adds "medical conditions of the same kind or class as or comparable to those enumerated in paragraphs (a)-(j)," which is a physician judgment about comparability to a listed condition. No addiction or withdrawal diagnosis appears anywhere in the section.
• Georgia. The Low THC Oil Registry conditions under O.C.G.A. 31-2A-18 do not include withdrawal or any substance use disorder.
• Texas. Occupations Code 169.003, as amended by HB 46 of 2025, does not list withdrawal or any substance use disorder.

The nearest analogue on the site is the opioid use disorder page. That is not a qualifying condition in Florida, Georgia, or Texas either, though a small number of other states have added it as a harm-reduction pilot. Nothing comparable exists for cannabis withdrawal in any state program.

Already hold a certification and noticing symptoms during a gap in use? Raise it at your next appointment. It is not, by itself, a basis for certification.

What This Means for Florida, Georgia, and Texas Patients

Tell the certifying physician if you have experienced these symptoms. In the Michigan cohort every patient presenting for certification or re-certification fell into one of the three withdrawal classes, and 59 percent landed in the moderate or severe class. This is a common presentation, not an unusual disclosure, and it informs the evaluation.

Do not read a medical certification as an exemption. The withdrawal literature describes exposure to THC-containing products at daily or near-daily frequency. It does not distinguish between a legal certified patient and anyone else with the same exposure pattern.

Know which wave you are in before you interpret it. Mood symptoms peaking two weeks after a gap in use is a documented pattern, not evidence that an underlying condition has worsened. Confusing the two can lead to a medication change nobody needed.

Age matters for what to expect. Younger age predicted both greater severity and a worsening trajectory in the only cohort that followed medical patients for two years.

Raise it with whoever manages your other prescriptions. Anxiety, irritability, depressed mood, and insomnia are all withdrawal features and all reasons a prescriber might otherwise adjust a psychiatric medication. The cannabis and antidepressants post covers why changes in cannabis use belong in that conversation in both directions.

Miracle Leaf® physicians evaluate patients for the Florida, Georgia, and Texas state programs, and your actual pattern of use is part of that evaluation.

What If You Live Outside Florida, Georgia, and Texas?

The symptoms and the timeline in this article are not state specific. Only the certification pathway is.

In a state where medical cannabis is legal but Miracle Leaf has no clinic? The telehealth program covers evaluations outside the Florida, Georgia, and Texas footprint. Bring the same information: how often you use, how long you have used at that frequency, and what happens during gaps.

Sources for Cannabis Withdrawal Symptoms and Duration

• Clinical management of cannabis withdrawal. Connor JP, Stjepanović D, Budney AJ, Le Foll B, Hall WD. Addiction. 2022;117(7):2075 to 2095. doi:10.1111/add.15743. PMCID PMC9110555. Source of the DSM-5 criteria table, the onset and peak timing, the two-wave symptom course, the statement that withdrawal does not carry a high risk of severe adverse outcomes, the genetic variation and sex findings, and the CBD cessation statement.
• Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP. JAMA Netw Open. 2020;3(4):e202370. doi:10.1001/jamanetworkopen.2020.2370. PMCID PMC7146100. Source of the 47 percent pooled prevalence, the 47 studies and 23,518 participants, the setting subgroups, the heterogeneity figure, and the moderator analysis.
• DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. Livne O, Shmulewitz D, Lev-Ran S, Hasin DS. Drug Alcohol Depend. 2019;195:170 to 177. doi:10.1016/j.drugalcdep.2018.09.005. PMID 30361043. PMCID PMC6359953. Source of the 12.1 percent NESARC-III prevalence among frequent users and the individual symptom percentages.
• The time course and significance of cannabis withdrawal. Budney AJ, Moore BA, Vandrey RG, Hughes JR. J Abnorm Psychol. 2003;112(3):393 to 402. doi:10.1037/0021-843X.112.3.393. PMID 12943018. Source of the 50-day design, the day 1 to 3 onset, day 2 to 6 peak, 4 to 14 day duration, and the tobacco comparison.
• Progression of cannabis withdrawal symptoms in people using medical cannabis for chronic pain. Coughlin LN, Ilgen MA, Jannausch M, Walton MA, Bohnert KM. Addiction. 2021;116(8):2067 to 2075. doi:10.1111/add.15370. PMID 33400332. PMCID PMC8363170. Source of the 527-patient cohort, the mild, moderate, and severe class proportions, the two-year stability estimates, and the younger-age finding.
• Cannabis (Marijuana) research topic. National Institute on Drug Abuse. Source of the withdrawal symptom list corroborating the DSM-5 features.
• Cannabis Use Disorder. StatPearls, NCBI Bookshelf. Corroborating source for the DSM-5 withdrawal criteria summary and the onset-to-resolution window.
• Changes in Cannabis Potency Over the Last 2 Decades (1995-2014). ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Biol Psychiatry. 2016;79(7):613 to 619. doi:10.1016/j.biopsych.2016.01.004. PMCID PMC4987131. Source of the 38,681 seized samples, the 4 percent to 12 percent THC trend, and the CBD ratio change.
• A 10-year trend in cannabis potency (2013-2022) in different geographical regions of the United States of America. ElSohly MA, Majumdar CG, Chandra S, Radwan MM. Front Public Health. 2024;12:1442522. doi:10.3389/fpubh.2024.1442522. PMCID PMC11484017.
• Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health. SAMHSA, Center for Behavioral Health Statistics and Quality. Source of the past-year cannabis use figures for 2021 and 2024.
• Fla. Stat. 381.986, Georgia Low THC Oil Registry conditions under O.C.G.A. 31-2A-18, and Texas HB 46 of 2025 amending Occupations Code 169.003. State qualifying condition lists.

Related Health and Eligibility Resources

• The how long does THC stay in your system post covers detection windows, which is a question about metabolite clearance rather than about symptoms.
• The cannabis and antidepressants post covers why a change in cannabis use, in either direction, belongs in a conversation with whoever prescribes your psychiatric medication.
• The is weed a depressant, stimulant, or hallucinogen post covers the pharmacological classification underneath the receptor effects described here.
• The does weed raise blood pressure post covers the cardiovascular history that belongs in the same pre-certification conversation.
• The qualifying conditions page covers eligibility across all three state programs, and each condition page shows whether that condition is listed in Florida, Georgia, and Texas.
• The Florida marijuana laws, Georgia marijuana laws, and Texas marijuana laws pages cover each program and its condition list.

Talk to a Physician About Your Cannabis Use

How often you use, how long you have used at that frequency, and what happens during gaps are all part of a certification evaluation. Bring them to the appointment rather than leaving them out.

Call (833) LEGAL-MJ or contact us online to book. Evaluation pricing is on the pricing page, and the clinicians who review this content are listed on the editorial team page.

Disclaimer

This post is informational and is not medical advice. It describes cannabis withdrawal symptoms and their documented time course. It does not assess whether cannabis is addictive, and it does not provide guidance on planning, managing, or medicating a cessation attempt, all of which require a clinician who knows your history. The prevalence figures cited describe study populations and do not predict what any individual will experience. The 47 percent pooled estimate comes from studies weighted toward treatment-seeking samples, with very high statistical heterogeneity. The medical cannabis cohort was a single predominantly white sample recruited in one state in 2014 and 2015. The potency figures describe cannabis seized by law enforcement, not regulated dispensary products, and no study has directly linked that trend to withdrawal prevalence. Cannabis withdrawal is not a qualifying condition in Florida, Georgia, or Texas. Do not start, stop, or change a prescribed medication based on this article. If you are experiencing thoughts of self-harm, contact the 988 Suicide and Crisis Lifeline immediately.